Analysts Set Cardiome Pharma Corp (CRME) Target Price at $6.31
Shares of Cardiome Pharma Corp (NASDAQ:CRME) (TSE:COM) have been assigned a consensus recommendation of “Buy” from the six ratings firms that are covering the stock. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have given a buy recommendation to the company. The average 1-year price objective among brokers that have covered the stock in the last year is $6.31.
Several analysts have recently commented on CRME shares. Zacks Investment Research cut Cardiome Pharma Corp from a “hold” rating to a “sell” rating in a research report on Friday, March 10th. HC Wainwright set a $10.00 target price on Cardiome Pharma Corp and gave the stock a “buy” rating in a research report on Wednesday, March 8th. Finally, Leerink Swann started coverage on Cardiome Pharma Corp in a research report on Thursday, December 22nd. They issued an “outperform” rating and a $4.75 target price for the company.
Shares of Cardiome Pharma Corp (NASDAQ:CRME) traded down 0.63% during trading on Monday, hitting $3.13. The stock had a trading volume of 56,447 shares. Cardiome Pharma Corp has a 12-month low of $2.35 and a 12-month high of $6.36. The stock has a 50-day moving average of $3.06 and a 200 day moving average of $2.92. The firm’s market cap is $99.85 million.
Cardiome Pharma Corp (NASDAQ:CRME) last issued its earnings results on Tuesday, March 7th. The biopharmaceutical company reported ($0.18) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by $0.02. The business earned $7 million during the quarter, compared to analyst estimates of $6.72 million. Cardiome Pharma Corp had a negative return on equity of 92.96% and a negative net margin of 93.43%. On average, analysts predict that Cardiome Pharma Corp will post ($0.54) earnings per share for the current fiscal year.
A number of hedge funds have recently added to or reduced their stakes in the stock. PNC Financial Services Group Inc. boosted its stake in Cardiome Pharma Corp by 49.0% in the third quarter. PNC Financial Services Group Inc. now owns 53,000 shares of the biopharmaceutical company’s stock worth $166,000 after buying an additional 17,420 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Cardiome Pharma Corp by 32.2% in the fourth quarter. Renaissance Technologies LLC now owns 215,013 shares of the biopharmaceutical company’s stock worth $593,000 after buying an additional 52,400 shares during the last quarter. Tamarack Advisers LP purchased a new stake in Cardiome Pharma Corp during the third quarter worth about $6,941,000. Finally, Stonepine Capital Management LLC boosted its stake in Cardiome Pharma Corp by 64.6% in the fourth quarter. Stonepine Capital Management LLC now owns 3,158,816 shares of the biopharmaceutical company’s stock worth $8,718,000 after buying an additional 1,240,094 shares during the last quarter. 62.21% of the stock is owned by hedge funds and other institutional investors.
Cardiome Pharma Corp Company Profile
Cardiome Pharma Corp. (Cardiome) is a specialty pharmaceutical company. The Company is engaged in the development and commercialization of cardiovascular therapies for heart disease. The Company’s segments are Europe and Rest of World. Cardiome has two marketed, in-hospital, cardiology products, which include BRINAVESS (vernakalant IV), approved in Europe and other territories for the conversion of onset atrial fibrillation (AF) to sinus rhythm in adults, and AGGRASTAT (tirofiban hydrochloride (HCl)), indicated for use in patients with acute coronary syndrome.
Receive News & Ratings for Cardiome Pharma Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cardiome Pharma Corp and related companies with Analyst Ratings Network's FREE daily email newsletter.